Anova, an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS™ technology platform, and the industry’s first collaborative ‘learning system’, today announced a partnership with Throne Biotechnologies, Inc. (Throne Bio, ThroneBio.com) to provide early access to Stem Cell Educator (SCE) Therapy for patients with Type 1 Diabetes and other life-threatening autoimmune diseases.

Throne Bio is a clinical stage biotechnology company developing innovative stem cell technologies to address diabetes and other autoimmune disorders.  As part of the partnership, Anova will support patient access to SCE Therapy when clinical trials are not an option due to study eligibility, proximity or other reasons.  The program will additionally gather important data that will further support the development of SCE therapy for the regulatory approval on commercialization by FDA.

“Our partnership with Throne is a further demonstration of Anova’s commitment to increasing access to promising new treatments for patients in need,’ said Martin Walsh, President at Anova.  ‘Partnering with Throne Bio will also generate quality data to inform product development across a range of serious auto-immune disorders.”

“We look forward to working with Throne Bio, and helping to accelerate development efforts.”